CLBX — Cellbxhealth Share News
0.000.00%
Last trade - 00:00- £17.38m
- £15.77m
- £2.86m
Brief: Angle PLC Sees Cash Runway Into Q1 2026
Preliminary Results
Notice of Results
RESULTS SUPPORTING ANGLE’S HER2 ASSAY PROGRAMME
Brief: Angle- Results Of Eisai Phase 2 Pilot study supports applicability of Parsortix-Based HER2 Assay For Use In ADC Clinical Trials
Issue of LTIP Options and Share Options
Results of Eisai Phase 2 pilot study
Novel findings using Parsortix
Berenberg predicts 'another eventful year' for MedTech sector
Analysis of CTC-DNA and ctDNA using Illumina assay
Parsortix used in research paper from ETH Zurich
Europe Research Roundup: Anglo American , Energean, Savills
Brief: Angle Expects Rev For 2024 To Be Up 31%
Brief: Angle FY Net Income GBP -14 Million
Trading Update
HER2 presentation at SABCS
Research on HER2 assay kit showcased at AACR
Parsortix based PD-L1 assay showcased at AACR
ANGLE presents two posters at EACR